Biotech | May 12, 2022
Mawi DNA Technologies launches NextSWAB for Covid-19 test results
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Revolutionary ovarian cancer rapid test available Q4 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The company exports mobile surgery equipment to over 100 countries from Pune
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The company also raised Rs 270 crore investment from Temasek in 2019
Subscribe To Our Newsletter & Stay Updated
